The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).

BACKGROUND: Isolated local failure (ILF) can occur in patients who initially receive definitive radiation therapy for prostate cancer. Salvage therapy for ILF includes high dose rate (HDR) brachytherapy. Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) can accurately dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendez, Lucas C., Dhar, Aneesh, Laidley, David, Moussa, Madeleine, Gomez, Jose A., Chin, Joseph, Lee, T-Y, Thiessen, Jonathan D., Hoover, Douglas, Surrey, Kathleen, Helou, Joelle, Velker, Vikram, Correa, Rohann J., D’Souza, David, Bayani, Jane, Bauman, Glenn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116658/
https://www.ncbi.nlm.nih.gov/pubmed/37081426
http://dx.doi.org/10.1186/s12885-023-10851-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116658/
https://www.ncbi.nlm.nih.gov/pubmed/37081426
http://dx.doi.org/10.1186/s12885-023-10851-0

Ejemplares similares